Newly Designed Geldanamycin Analogues for Targeted Cancer-Causing Hsp90 Protein Inhibitor: Molecular Docking Study
-
Published:2022-03-21
Issue:
Volume:914
Page:111-116
-
ISSN:1662-9795
-
Container-title:Key Engineering Materials
-
language:
-
Short-container-title:KEM
Author:
Suttayasorranakhom Satipat1, Jaramornburapong Chanjira2, Phuthawong Waya1, Sirirak Jitnapa1
Affiliation:
1. Silpakorn University 2. Nakhon Pathom Rajabhat University
Abstract
Cancer is currently a major public health concern worldwide. Previous studies have shown that heat shock protein 90 (Hsp90) is the key common cause of cancer. Thus, Hsp90 is one of the important molecular targets for the development of Hsp90 cancer drug based on geldanamycin (GDM) and alvespimycin (17-DMAG). Herein, novel geldanamycin derivatives, S1-S6 were designed as potential Hsp90 cancer drug by targeting signal transduction pathway, especially against oncogenic client protein from Hsp90. The binding of S1-S6 in the cavity of Hsp90 were investigated by molecular docking using the iGEMDOCK v2.1 software. The results illustrated that S1-S6 bound in the binding site of Hsp90 with similar manner to GDM and 17-DMAG. The binding energies of S1-S6 in Hsp90 (PDB ID:1YET) (-137.49 to -123.24 kcal/mol) were comparable to that of GDM (-133.06 kcal/mol) while the binding energies of S1-S6 in Hsp90 (PDB ID:1OSF) (-137.49 to -131.22 kcal/mol) were slightly higher than that of 17-DMAG (-145.31 kcal/mol). S1-S6 interacted well by hydrogen bonding with key amino acids in the binding site of Hsp90, which could inhibit the cancer cell growth. Therefore, S1-S6 containing novel geldanamycin derivatives could be promising molecules for anti-cancer drug against Hsp90 2 types in the future.
Publisher
Trans Tech Publications, Ltd.
Subject
Mechanical Engineering,Mechanics of Materials,General Materials Science
Reference16 articles.
1. P. Anand, A.B. Kunnumakkara, C. Sundaram, K.B. Harikumar, S.T. Tharakan, O.S. Lai, B. Sung, B.B. Aggarwal, Cancer is a preventable disease that requires major lifestyle changes, Pharm. Res., 25(9), 2008, 2097-2116. 2. C. Chavany, E. Mimnaugh, P. Miller, R. Bitton, P. Nguyen, J. Trepel, L. Whitesell, R. Schnur, J. Moyer, L. Neckers, p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2, J. Biol. Chem., 271, 1996, 4974-4977. 3. B. Segnitz, U. Gehring, The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin, J. Biol. Chem, 272, 1997, 18694-18701. 4. P. Miller, C. DiOrio, M. Moyer, R.C. Schnur, A. Bruskin, W. Cullen, J.D. Moyer, Depletion of the erbB-2 gene product p.185 by benzoquinoid ansamycins, Cancer Res., 54, 1994, 2724-2730. 5. P. Csermely, T. Schnaider, C. Sõti, Z. Prohászka, G. Nardai, The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review, Pharmacol. Ther., 79(2), 1998, 129-168.
|
|